Here is the design of a clinical trial:

Official Title: Clinical Evidence-based Evaluation of the Efficacy of Shenbai Granules in Preventing Recurrent Colorectal Adenomas After Polypectomy and Its Therapeutic Mechanism

Included conditions:
- Gastroenterology

Study Armgroups:
- {'label': 'TCM-Shenbai Granules', 'type': 'EXPERIMENTAL', 'description': 'Shenbai Granules: Hedyotis diffusa 10g, Sophorae flavescentis radix 4.5g, Codonopsis radix 7.5g, Atractylodis macrocephalae rhizoma 6g, Mume fructus 4.5g, Coptidis rhizoma 1.5g, Zingiberis rhizome praeparatum 3g, Coicis semen 10g.\n\nOrally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day.', 'interventionNames': ['Drug: Shenbai Granules']}
- {'label': 'TCM-Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'It contains 5% SBG content, and the remaining ingredients are flavoring agents, starch and coloring agents. It is the same with SBG in appearance, smell and dosage form.\n\nOrally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day.', 'interventionNames': ['Drug: Shenbai Granules']}

Interventions:
- {'type': 'DRUG', 'name': 'Shenbai Granules', 'description': 'In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.', 'armGroupLabels': ['TCM-Placebo', 'TCM-Shenbai Granules'], 'otherNames': ['placebo']}

Primary Outcomes:
- {'measure': 'Adenoma detection rate', 'description': 'The ratio of the number of patients with new adenoma detected by colonoscopy to the total number of cases in this group during follow-up.', 'timeFrame': '2 years'}

Please estimate the sample size based on the assumption: 
A 2-sided significance level of 0.05 and power of 90% (α = 0.05, β = 0.1) with a 20% loss to follow-up.
2.4
        Sample size
        According to the literature search, new CAP occurrence in post-polypectomy was used as the scoring criteria for the treatment of polypectomy under colonoscopy. The new CAP occurrence rate under colonoscopy treatment was about 30% (P0), and the new CAP occurrence after the intervention with Xiaoai Jiedu Decoction was about 16.4% (P1). According to the 1:1 parallel control principle, for a 2-sided significance level of .05 and power of 90% (Î±â=â0.05, Î²â=â0.1), the sample size is calculated using the formula:Â 
        Considering a 20% loss to follow-up, the sample size is 400 cases (nâ=â200 in each group).